注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Relay Therapeutics Inc是一家临床级精密药物公司。该公司致力于改变药物发现过程,最初的重点是增强靶向肿瘤学中的小分子治疗发现。该公司正在推进一条针对精确肿瘤学目标的药物管道,包括其主要候选产品RLY-4008、RLY-2608和RLY-1971。其RY-1971结合并稳定含有Src同源区二(SH2)的蛋白酪氨酸磷酸酶二(SHP2)的非活性构象。它的RLY-4008是成纤维细胞生长因子受体二(FGFR2)的抑制剂,为具有致癌性FGFR2的晚期实体瘤患者富集。该公司利用其Dynamo平台专注于精确肿瘤学。它还推进了几个早期项目,重点关注其他精确的肿瘤学和遗传疾病目标。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Mark Murcko | 61 | 2016 | Co-Founder & Director |
Douglas S. Ingram | 58 | 2019 | Independent Director |
Linda A. Hill | 64 | 2018 | Independent Director |
Jamilu E. Rubin | 57 | 2019 | Independent Director |
Laura K. Shawver | 63 | 2017 | Independent Director |
Pamela Munster | - | 2020 | Member of Oncology Advisory Board |
Jean-Charles Soria | 50 | 2020 | Member of Oncology Advisory Board |
Trever Bivona | - | 2020 | Member of Oncology Advisory Board |
Lillian L. Siu | - | 2020 | Member of Oncology Advisory Board |
George Daniel Demetri | 64 | 2020 | Member of Oncology Advisory Board |
Nikhil Wagle | - | 2020 | Member of Oncology Advisory Board |
Dejan Juric | - | 2020 | Member of Oncology Advisory Board |
Sekar Kathiresan | 50 | 2022 | Independent Director |
Alexis A. Borisy | 52 | 2015 | Co-Founder & Independent Chairman |
Sanjiv K. Patel | 50 | 2017 | CEO, President & Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核